Tech Company Financing Transactions

Black Diamond Therapeutics Funding Round

On 1/11/2019, Black Diamond Therapeutics raised $85 million in Series B funding from New Enterprise Associates, RA Capital and Invus.

Transaction Overview

Announced On
1/11/2019
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (Ali Behbahani)

RA Capital (Lead Investor) (Rajeev Shah)

Invus

Nextech Invest

Perceptive Advisors

Versant Ventures (Alex Mayweg)

Proceeds Purpose
Proceeds from the financing will be used to accelerate the development of Black Diamond's pipeline and to expand its mutation, allostery and pharmacology (MAP) computational and discovery platform for identifying and targeting allosteric oncogenic mutations.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
139 Main St. 301
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Black Diamond Therapeutics (Nasdaq: BDTX): A Next-Wave Cancer Precision Medicine Company. Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
Profile
Black Diamond Therapeutics LinkedIn Company Profile
Social Media
Black Diamond Therapeutics Company Twitter Account
Company News
Black Diamond Therapeutics News
Facebook
Black Diamond Therapeutics on Facebook
YouTube
Black Diamond Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Epstein
  David Epstein LinkedIn Profile  David Epstein Twitter Account  David Epstein News  David Epstein on Facebook
Chief Financial Officer
Thomas Leggett
  Thomas Leggett LinkedIn Profile  Thomas Leggett Twitter Account  Thomas Leggett News  Thomas Leggett on Facebook
Chief Operating Officer
Brent Hatzis-Schoch
  Brent Hatzis-Schoch LinkedIn Profile  Brent Hatzis-Schoch Twitter Account  Brent Hatzis-Schoch News  Brent Hatzis-Schoch on Facebook
Chief Scientific Officer
Christopher Roberts
  Christopher Roberts LinkedIn Profile  Christopher Roberts Twitter Account  Christopher Roberts News  Christopher Roberts on Facebook
Executive Vice President
Elizabeth Buck
  Elizabeth Buck LinkedIn Profile  Elizabeth Buck Twitter Account  Elizabeth Buck News  Elizabeth Buck on Facebook
Vice President
Tai-An Lin
  Tai-An Lin LinkedIn Profile  Tai-An Lin Twitter Account  Tai-An Lin News  Tai-An Lin on Facebook
Vice President
Matthew Lucas
  Matthew Lucas LinkedIn Profile  Matthew Lucas Twitter Account  Matthew Lucas News  Matthew Lucas on Facebook
Vice President
Nigel Waters
  Nigel Waters LinkedIn Profile  Nigel Waters Twitter Account  Nigel Waters News  Nigel Waters on Facebook
Vice President
Karsten Witt
  Karsten Witt LinkedIn Profile  Karsten Witt Twitter Account  Karsten Witt News  Karsten Witt on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/11/2019: Piano Software venture capital transaction
Next: 1/14/2019: First Stop Health venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary